Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients

Abstract Introduction HER2-positive breast cancer (HPBC) occurs in 20–25% of breast cancer patients and is characterized by a poor prognosis. Trastuzumab is a key drug for treating HPBC; however, resistance to trastuzumab is challenging in patients. This study aimed to investigate the effect of HER2...

Full description

Bibliographic Details

Published in:	Egyptian Journal of Medical Human Genetics
Main Authors:	Zohreh Gheibipour, Tina Vosoughi, Gholamreza Shariati, Mehran Hoseinzadeh, Mohammad Reza Mahmoudian-Sani, Mahdi Bijanzadeh
Format:	Article
Language:	English
Published:	SpringerOpen 2025-07-01
Subjects:	HER2-positive breast cancer Trastuzumab Ile655Val polymorphism
Online Access:	https://doi.org/10.1186/s43042-025-00746-z